By Region, the study provides market insights into Europe, North America, Asia-Pacific, and the Rest of the World. The North American intravenous solution market is expected to grow at a significant CAGR during the projection period, accounting for USD 2.8 billion in 2021. This is due to an increase in the geriatric population, which increases demand for intravenous solutions, the rising incidence of chronic diseases, and the industry's expansion to meet the rising demands caused by the flu and coronavirus pandemics.
North America is a highly developed region with a well-established healthcare infrastructure, which has resulted in an increased demand for IV treatment throughout its life cycle during various stages, such as emergency care or surgery.
In addition, the major countries covered in the intravenous solution market are the United States, Germany, France, Canada, the United Kingdom, India, Spain, Italy, Japan, Australia, China, South Korea, and Brazil.
Figure 3: Intravenous Solution Market Share By Region 2021 (%)
Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review
Europe has the world's second-largest intravenous solution market, owing to increasing intravenous solution sales volume in the region due to the region's aging population and correlating growth of the patient pool. This is because the healthcare system has a large patient population, a strong presence of key players, easy drug availability, well-developed healthcare systems, and favorable reimbursement policies. Moreover, technological advancements in the industry and government assistance for the National Health Service and health insurance will likely drive growth in the European intravenous (IV) solutions market.
Further, the U.K. intravenous solution market held the largest market share, and the France intravenous solution market was the fastest-growing market in the European region.
The Asia Pacific intravenous solution market is predicted to expand at the fastest CAGR in the forecast period. The presence of high expenditure by both public and private entities in the research sector, as well as technological advancements and an increasing number of collaborative relationships between various stakeholders, such as the healthcare community, universities, and others, can be attributed to this region's rapid growth. Another important factor anticipated to drive market growth in the Asia Pacific region is the rising prevalence of chronic diseases brought on by unhealthy food consumption patterns and the growing preference for cost-effective care.
